213 related articles for article (PubMed ID: 28064545)
21. Androgen receptor signaling regulates cell growth and vulnerability to doxorubicin in bladder cancer.
Shiota M; Takeuchi A; Yokomizo A; Kashiwagi E; Tatsugami K; Kuroiwa K; Naito S
J Urol; 2012 Jul; 188(1):276-86. PubMed ID: 22608749
[TBL] [Abstract][Full Text] [Related]
22. Transcribed ultraconserved region Uc.63+ promotes resistance to cisplatin through regulation of androgen receptor signaling in bladder cancer.
Sekino Y; Sakamoto N; Ishikawa A; Honma R; Shigematsu Y; Hayashi T; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
Oncol Rep; 2019 May; 41(5):3111-3118. PubMed ID: 30864720
[TBL] [Abstract][Full Text] [Related]
23. Sex Hormone Receptor Signaling in Bladder Cancer: A Potential Target for Enhancing the Efficacy of Conventional Non-Surgical Therapy.
Ide H; Miyamoto H
Cells; 2021 May; 10(5):. PubMed ID: 34064926
[TBL] [Abstract][Full Text] [Related]
24. Role of androgen receptor expression in non-muscle-invasive bladder cancer: a systematic review and meta-analysis.
Sanguedolce F; Cormio L; Carrieri G; Calò B; Russo D; Menin A; Pastore AL; Greco F; Bozzini G; Galfano A; Pini G; Porreca A; Mugavero F; Falsaperla M; Ceruti C; Cindolo L; Antonelli A; Minervini A
Histol Histopathol; 2020 May; 35(5):423-432. PubMed ID: 31803932
[TBL] [Abstract][Full Text] [Related]
25. Histopathological and prognostic significance of the expression of sex hormone receptors in bladder cancer: A meta-analysis of immunohistochemical studies.
Ide H; Inoue S; Miyamoto H
PLoS One; 2017; 12(3):e0174746. PubMed ID: 28362839
[TBL] [Abstract][Full Text] [Related]
26. Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells.
Zheng Y; Izumi K; Yao JL; Miyamoto H
Endocr Relat Cancer; 2011 Aug; 18(4):451-64. PubMed ID: 21613411
[TBL] [Abstract][Full Text] [Related]
27. Androgen signaling and its interactions with other signaling pathways in prostate cancer.
Kaarbø M; Klokk TI; Saatcioglu F
Bioessays; 2007 Dec; 29(12):1227-38. PubMed ID: 18008377
[TBL] [Abstract][Full Text] [Related]
28. Managing noninvasive recurrences after definitive treatment for muscle-invasive bladder cancer or high-grade upper tract urothelial carcinoma.
DiBianco JM; George AK; Su D; Agarwal PK
Curr Opin Urol; 2015 Sep; 25(5):468-75. PubMed ID: 26125507
[TBL] [Abstract][Full Text] [Related]
29. Androgen Receptor Signaling Induces Cisplatin Resistance via Down-Regulating GULP1 Expression in Bladder Cancer.
Teramoto Y; Jiang G; Goto T; Mizushima T; Nagata Y; Netto GJ; Miyamoto H
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576193
[TBL] [Abstract][Full Text] [Related]
30. The effect of gender on response to bacillus Calmette-Guérin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder.
Boorjian SA; Zhu F; Herr HW
BJU Int; 2010 Aug; 106(3):357-61. PubMed ID: 20002665
[TBL] [Abstract][Full Text] [Related]
31. Androgen Receptor Signaling in Bladder Cancer.
Li P; Chen J; Miyamoto H
Cancers (Basel); 2017 Feb; 9(2):. PubMed ID: 28241422
[TBL] [Abstract][Full Text] [Related]
32. Androgen Receptor Predicts First and Multiple Recurrences in Non-Muscle Invasive Urothelial Carcinoma of the Bladder.
Yonekura S; Terauchi F; Hoshi K; Yamaguchi T; Kawai S
Pathol Oncol Res; 2019 Jul; 25(3):987-994. PubMed ID: 29862474
[TBL] [Abstract][Full Text] [Related]
33. Recent advances in the understanding of urothelial tumorigenesis.
Yasui M; Cui L; Miyamoto H
Expert Rev Anticancer Ther; 2023 May; 23(5):485-493. PubMed ID: 37052619
[TBL] [Abstract][Full Text] [Related]
34. Evolution of the concept of androgen-sensitive bladder cancer.
Gakis G; Stenzl A; Renninger M
Scand J Urol; 2013 Jun; 47(3):173-8. PubMed ID: 23330817
[TBL] [Abstract][Full Text] [Related]
35. Androgen Receptor Signaling Reduces Radiosensitivity in Bladder Cancer.
Ide H; Inoue S; Mizushima T; Jiang G; Chuang KH; Oya M; Miyamoto H
Mol Cancer Ther; 2018 Jul; 17(7):1566-1574. PubMed ID: 29720561
[TBL] [Abstract][Full Text] [Related]
36. FOXO1 as a tumor suppressor inactivated via AR/ERβ signals in urothelial cells.
Ide H; Mizushima T; Jiang G; Goto T; Nagata Y; Teramoto Y; Inoue S; Li Y; Kashiwagi E; Baras AS; Netto GJ; Kawahara T; Miyamoto H
Endocr Relat Cancer; 2020 Apr; 27(4):231-244. PubMed ID: 32031965
[TBL] [Abstract][Full Text] [Related]
37. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
38. Androgen receptor signaling in prostate cancer.
Culig Z; Santer FR
Cancer Metastasis Rev; 2014 Sep; 33(2-3):413-27. PubMed ID: 24384911
[TBL] [Abstract][Full Text] [Related]
39. Androgen axis in prostate cancer.
Culig Z; Bartsch G
J Cell Biochem; 2006 Oct; 99(2):373-81. PubMed ID: 16598769
[TBL] [Abstract][Full Text] [Related]
40. Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor.
Hsu JW; Hsu I; Xu D; Miyamoto H; Liang L; Wu XR; Shyr CR; Chang C
Am J Pathol; 2013 May; 182(5):1811-20. PubMed ID: 23499463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
